by Jordana Choucair | Feb 14, 2022 | Life Sciences
The FDA on Friday authorized a new monoclonal antibody treatment to treat mild to moderate COVID-19 symptoms. The drug, developed by Eli Lilly, should be used to treat patients ages 12 and older “for whom alternative COVID-19 treatment options approved or...
by Jordana Choucair | Feb 14, 2022 | Life Sciences
The FDA delayed its decision on authorizing Pfizer-BioNTech’s COVID-19 vaccine for children under five years old. The agency stated, “Based on the agency’s preliminary assessment, and to allow more time to evaluate additional data, we believe additional...
by Jordana Choucair | Feb 11, 2022 | Life Sciences
The Biden administration bought enough of an experimental monoclonal antibody drug from Eli Lilly & Co. to treat 600,000 COVID-19 patients. According to health officials, the treatment to be shipped to states for free if it’s authorized by regulators. The...
by Jordana Choucair | Feb 10, 2022 | Life Sciences
The CDC plans to roll out 10 million doses of Pfizer Inc.-BioNTech SE’s COVID-19 vaccine for young children in three phases as soon as the FDA authorizes the shots. According to an agency planning document, states could begin receiving vaccine shipments on...
by Jordana Choucair | Feb 7, 2022 | Life Sciences
The FDA will restart its domestic pharma-related surveillance inspections today after pausing the program in December. The agency has been stopping and starting since the COVID-19 pandemic began to “ensure the safety of its employees and those of the firms it...
by Jordana Choucair | Feb 4, 2022 | Life Sciences
Eli Lilly and Co. pushed back its timeline to ask regulators to grant accelerated approval to its experimental Alzheimer’s disease drug. The drugmakers said approval would have little impact on its business this year given Medicare officials’ decision to...
Recent Comments